newsletters.drugs.com/l/HXd...
"Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action.*
The ability to reply to this post has been turned off.
JerrysGirl, The news about FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies, has already been posted about here; healthunlocked.com/cllsuppo...
I'm closing off discussion on this post and have added a link to the drugs.com in that post, to keep discussion on this important topic in one place.
I've also changed your post title, to describe the content.
Of note, our community guideline item 19 notes;
"If you post a link, please at least explain briefly what people can expect to find if they follow the link. Links without such an introduction/explanation may be deleted."
cllsupport.org.uk/informati...
Neil
EHA 2019: Dr. Maloney on CAR-T and Dr. Davids of Chemo-Immunotherapy combinations 
More on Cytokine Release Syndrome toxicities associated with CAR-T-cell therapy.
Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapyFeeling nasty after my third and final day of lymphs-depleting chemo (FC) before my CAR-T cells on March 22
Infection risk and SLL
